NNMT is an enzyme that catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide (NAM), producing 1-methylnicotinamide (MNA) and S-adenosylhomocysteine (SAH)
Since attaining approval by the Chinese Food and Drug Administration in 2011, icotinib, marketed under the brand name Conmana, has reported to have over a third of the Chinese market share in lung cancer therapies.[1] The US patent application for the preparation of icotinib and icotinib hydrochloride was filed on December 28, 2012 and the patent was granted on July 21, 2015.[2] There are currently no active or recruiting clinical trials for icotinib in the United States.[3] Currently, icotinib is the only marketed drug product from Betta Pharmaceuticals, primarily accounting for the companys $1.289 billion earnings in sales in 2016.[4] Beta Pharma owns the international development and production rights of icotinib outside of China
As always, patients should work closely with their healthcare providers to determine if this therapy is right for them, weigh the benefits against side effects, and ensure its integrated safely with their overall care
Food and Drug Administration (FDA) sent a Warning Letter to Jacob Teitelbaum, M.D
Thats why more patients in Miami Beach are exploring a regenerative alternative: PRP therapy
At what point does the federal government have the limit to their power, if they can just go ahead and impose this on the entire private economy through an executive fiat?" DeSantis said during an appearance in Jacksonville
